Abelacimabis a novel fully human monoclonal antibody that acts as a dual inhibitor of Factor XI and Factor XIa.
It targets the catalytic domain of Factor XI, preventing its activation and thereby reducing the levels of functional Factor XI.
It is a hemostasis-sparing anticoagulation approach, which is particularly useful in the prevention and treatment of thromboembolic events.
Clinical studies have demonstrated that abelacimab is effective in reducing the risk of venous thromboembolism (VTE) postoperatively:superior to enoxaparin in preventing postoperative VTE after total knee arthroplasty, with a lower incidence of thrombosis and a comparable safety profile regarding bleeding risks.
Pharmacokinetic and pharmacodynamic studies indicate that abelacimab has a long terminal elimination half-life of 25 to 30 days, and it significantly reduces free FXI levels shortly after administration.
Among patients with atrial fibrillation, who were at moderate to high risk for stroke, treatment with abelacimab resulted in markedly lower levels of free factor XI in few bleeding events, then treatment with rivaroxaban.
Both intravenous and subcutaneous administrations have been shown to be safe and well-tolerated in clinical trials.